AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (currently amended) An endovascular implant, comprising:
   a) a tubular main body having open front sides and comprising at least one biodegradable material made of a metallic alloy, the main body having a location-dependent first degradation characteristic $D_1(x)$ in vivo; and
   b) a coating, which at least partially covers the main body, the coating comprising at least one biodegradable material, the coating having a location-dependent second degradation characteristic $D_2(x)$ in vivo,

   wherein a location-dependent cumulative degradation characteristic D(x) results at a location (x) from the sum of the particular existing degradation characteristics $D_1(x)$ and $D_2(x)$ existing at the cited location (x) and the location-dependent cumulative degradation characteristic D(x) is predefined by variation of the second degradation characteristic $D_2(x)$ in such way that the degradation at the cited location (x) of the implant occurs in a predefinable time interval having a predefinable degradation curve.

2. (previously presented) The implant of Claim 1, wherein the degradation characteristic $D_2(x)$ of the coating is provided by varying its morphological structure, material modification of the material, or adapting a layer thickness of the coating.

3. (previously presented) The implant of Claim 1, wherein the degradation characteristic $D_2(x)$ of the coating is predefined as a function of the pathophysiological conditions to be expected in application.

4. (previously presented) The implant of Claim 1, wherein the degradation characteristic $D_2(x)$ of the coating is predefined as a function of the rheological conditions to be expected in application.

5. (previously presented) The implant of Claim 2, wherein the degradation characteristic $D_2(x)$ of the coating is predefined as a function of the pathophysiological conditions to be expected in application.

6. (currently amended) The implant of Claim 2, wherein the degradation characteristic $D_2(x)$ of the coating is predefined as a function of the ~~pathophysiological~~ rheological conditions to be expected in application.

7. (new) The implant of Claim 1, wherein the metallic alloy includes at least one material selected from the group consisting of magnesium, iron, tungsten and WE43.

8. (new) The implant of Claim 1, wherein the coating includes an alloy comprising at least one material selected from the group consisting of magnesium, iron, tungsten and WE43.

9. (new) The implant of Claim 1, wherein the coating comprises at least one material selected from the group consisting of cellulose, collagen, albumin, casein, polysaccharides (PSAC), polylactide (PLA), poly-L-lactide (PLLA), polyglycol (PGA), poly-D,L-lactide-co-glycolide (PDLLA/PGA), polyhydroxy butyric acid (PHB), polyhydroxy valeric acid (PHV), polyalkylcarbonates, polyorthoester, polyethylenterephthalate (PET), polymalonic acid (PML), polyanhydrides, polyphosphazenes, polyamino acids and their copolymers, hyaluronic acid, and derivatives, blends and copolymers of the foregoing.

10. (new) The implant of Claim 1, wherein the coating comprises at least two biodegradable polymeric or metallic materials, wherein each material is disposed on the main body at either different locations or as multilayer systems at specific distinct locations on the main body.

11. (new) The implant of Claim 1, wherein the surface of the at least one coating is porous.